Novartis Sues To Protect Market For Epilepsy Drug

Law360, New York (September 6, 2006, 12:00 AM EDT) -- Novartis AG has filed a patent infringement suit in federal court in New Jersey to stave off generic competition for its popular antiepileptic drug Trileptal, which hauled in $352 million in sales in the first half of 2006.

The lawsuit targets Haifa Bay, Israel-based Taro Pharmaceutical Industries Ltd. and its U.S. subsidiary, and alleges that the defendants infringed a Novartis patent when they filed an Abbreviated New Drug Application seeking approval to make and sell generic oxacarbazepine—Trileptal’s active ingredient.

At issue is U.S. Patent No. 7,037,525,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.